Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 14/20 | 0.61 |
| ▸ | FER | P16591 | 6/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18925293 | 0.93 | SYK (0.52) | SYKFER | |
| SCHEMBL14929772 | 0.91 | SYK (0.73) | SYKFER | |
| SCHEMBL14909090 | 0.91 | SYK (0.73) | SYKFER | |
| SCHEMBL5027982 | 0.91 | SYK (0.73) | SYKFER | |
| SCHEMBL18925674 | 0.90 | SYK (0.59) | SYKFER | |
| SCHEMBL18925321 | 0.90 | SYK (0.51) | SYK | |
| SCHEMBL14929580 | 0.89 | SYK (0.71) | SYKFER | |
| SCHEMBL14909344 | 0.89 | SYK (0.71) | SYKFER | |
| SCHEMBL14909342 | 0.89 | SYK (0.71) | SYKFER | |
| SCHEMBL18925339 | 0.89 | SYK (0.53) | SYKFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3176154-B1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | PORTOLA PHARM INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-3176154-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | Portola Pharmaceuticals, Inc. (US) | 2017-06-07 | — | — | EP | disclosed |
| US-20150272956-A1 | SUBSTITUTED XANTHINE DERIVATIVES | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150272956-A1 | SUBSTITUTED XANTHINE DERIVATIVES | XDH, HPRT1, CXCR3 | SYK 2450/4885FER 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.